Prime Medicine is a biotechnology company developing genetic medicines based on Prime Editing, a gene editing technology that modifies genomic DNA without introducing double-stranded breaks. The company focuses on in vivo programs targeting liver diseases and Cystic Fibrosis, as well as ex vivo programs for hematologic disorders. Its lead program, PM577, targets Wilson Disease by correcting the H1069Q mutation in the ATP7B gene, while PM647 addresses alpha-1 antitrypsin deficiency. The company is also advancing a program for Cystic Fibrosis using lipid nanoparticles or adeno-associated viruses for delivery. Prime Medicine maintains a partnership with Bristol-Myers Squibb to apply Prime Editing to ex vivo T-cell engineering, with early clinical data from the PM359 program for Chronic Granulomatous Disease demonstrating restoration of functional protein activity. The company utilizes a modular platform to support rapid iteration and standardized manufacturing across its pipeline, aiming to provide durable treatment options for diseases driven by defined genetic alterations.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage primemedicine.com
Sector Healthcare IR page primemedicine.com
Tags
gene editing, prime editing, genetic diseases, liver diseases, cystic fibrosis, wilson disease, alpha-1 antitrypsin deficiency, hematologic disorders, in vivo therapy, ex vivo therapy, lipid nanoparticles, adeno-associated viruses, PM577, PM647, PM359, pegRNA, Bristol-Myers Squibb, Cystic Fibrosis Foundation
Press page —

Metrics

Valuation  
Market cap $ 554.132M
Market cap (USD) $ 554.132M
P/E -3.18
PEG —
P/BV 65.68
P/S 119.63
P/OCF -3.51
P/FCF -3.50
Dividend yield —
Turnover / mcap —
Returns  
ROE -146.8%
ROI -121.1%
ROIC -94.1%
Profit margin -4,342.4%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 25
Quality score -53.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Revenue 4.632M 2.983M — 0 0
Net profit -201.142M -195.882M -198.133M -121.821M -165.367M
Free cash flow -167.095M -130.159M -174.136M -147.922M -38.232M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Share price 3.47 2.92 8.86 18.58 —
Price performance 12m 0.19 -0.67 -0.52 — —

Filed figures

Figure Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) — 2.7M 10.4M 28.7M 13.6M 40.8M 116M
Cash and deposits (USD) 8.65M 37M 185M 188M 41.6M 182M 63M
Right-of-use assets (USD) — 2.8M 10.7M 29.5M 13.9M 47.2M 126M
Cash flow detail
Operating cash flow (USD) — -5.54M -34.1M -132M -165M -123M -163M
Purchases of property, plant and equipment (USD) — -639,000 -4.15M -16.1M -8.72M -7.29M -4.53M
Change in payables (cash effect) (USD) — 250,000 1.19M 2.46M 9.14M -5.26M 996,000
Income taxes paid (cash effect) (USD) — 0.00 0.00 -141,000 0.00 — —
Share-based compensation (USD) — 391,000 1.75M 6.46M 13.9M 26.1M 29.3M
Free cash flow (OCF - PPE - intangibles) (USD) — -6.18M -38.2M -148M -174M -130M -167M
Income detail
Research and development expense (USD) — 2.98M 70.6M 86.7M 148M 155M 161M
↳ 5y CAGR +122.0%
Total comprehensive income (USD) — -3.41M -165M -122M -198M -196M -201M
Comprehensive income to owners (USD) — -3.41M -165M -122M -198M -196M -201M
Reported Mar 9, 2023 Mar 9, 2023 Mar 9, 2023 Mar 9, 2023 Mar 1, 2024 Feb 28, 2025 Mar 3, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

-- First patient dosed in global Phase 1/2 clinical trial of PM577a in Wilson disease, the first clinical study of an in vivo Prime Editing therapy from Prime Medicine; initial clinical data expected in 2027 --

-- Received FDA clearance of Investigational New Drug application for PM647 in Alpha-1 Antitrypsin Deficiency; initial clinical data expected in 2027 --

-- Planning for a BLA submission for PM359 in the first half of 2027 --

-- Closed underwritten public offering, including the full exercise of the underwriters’ option to purchase additional shares, raising $143.7 million in gross proceeds --

-- Pro-forma cash, cash equivalents, investments and restricted cash of approximately $209.5 million; cash runway through 2027 --

Cambridge, Mass., November 12, 2026 – Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results for the quarter ended September 30, 2026 and provided a business update.

On November 10, 2026, Prime Medicine, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Jefferies LLC, TD Securities (USA) LLC and Goldman Sachs & Co. LLC, as representatives of the several underwriters listed on Schedule 1 thereto (collectively, the “Underwriters”), related to an underwritten public offering (the “Offering”) of 35,714,286 shares (the “Underwritten Shares”) of the Company’s common stock, par value $0.00001 per share (“Common Stock”), at a public offering price of $3.50 per share. In addition, the Company has granted the Underwriters an option, exercisable in whole or in part at any time for a period of 30 days from the date of the Underwriting Agreement, to purchase, at the public offering price, less the underwriting discounts and commissions, up to an additional 5,357,142 shares of Common Stock (the “Option Shares” and together with the Underwritten Shares, the “Shares”).

On November 10, 2026, Prime Medicine, Inc. (the “Company”) announced that the preliminary unaudited estimates of its cash, cash equivalents, and short-term investments were approximately $61.2 million as of September 30, 2026, excluding its restricted cash of approximately $13.7 million. The Company has not yet completed its quarter-end financial close process for the quarter ended September 30, 2026. The foregoing information is based on preliminary unaudited information and management estimates as of and for the quarter ended September 30, 2026, is not a comprehensive statement of the Company’s financial results, and is subject to completion of the Company’s financial closing procedures. There can be no assurance that the Company’s actual financial results as of September 30, 2026 will not differ from these estimates, including as a result of the completion of the Company’s final adjustments, and other developments arising between the date of this filing and the time that the Company’s financial results for such period are finalized, and any such changes could be material.

Prompts

Prime Medicine, Inc. (ticker PRME), listed in United States.

ETFs Holding Prime Medicine, Inc.

ETF Weight in ETF Shares Market value As of
ARKG 2.13% 10,107,354 $ 38.812M Nov 18, 2026
NXTE 0.87% 134,719 $ 497.113K Jun 30, 2026
TMED 0.10% 6,152 $ 22.701K Jun 30, 2026
ESSC 0.09% 11,637 $ 33.98K Jul 31, 2026
RESM 0.01% 111 $ 409.59 Jun 30, 2026
DCOR 0.00% 3,143 $ 12.226K Nov 12, 2026